Dr. Bernard Horowitz is a founding member of Horowitz Consultants, LLC, an organization that provides assistance in strategic planning, process development and the evaluation of biological products, all aspects of product viral safety and new product regulatory compliance. Most recently, he was a director of Omrix Therapeutics (a NASDAQ-listed company) prior to its purchase in December, 2008 by Johnson and Johnson. He also served on the Board of Directors of Biogentis, Inc., Dermacor, Inc., Protein Therapeutics, and V.I. Technologies (VITEX), a publicly held company he helped found. At its formation, he joined VITEX as Executive Vice President and Chief Scientific Officer. Prior to joining VITEX, Dr. Horowitz was the NYBC’s Vice President for Commercial Development and a Laboratory Head in the NYBC’s Lindsley F. Kimball Research Institute. He is recognized internationally for his research on blood viral safety and the preparation and characterization of new therapeutics from blood, and he holds over 25 U.S. patents for these processes. Dr. Horowitz has authored over 70 scientific publications and reviews on a wide range of subjects including: virus inactivation in blood proteins and cells, hepatitis B virus detection, the role of fibronectin in sepsis and wound healing, hemoglobin as a blood substitute, and the preparation and characterization of coagulation factors and of leukocyte interferon as an antiviral and anticancer agent. Additionally, he has served as a scientific consultant to the National Institutes of Health, the Food and Drug Administration, the National Hemophilia Foundation, the International Association of Biological Standardization, and the World Health Organization. Dr. Horowitz is the recipient of several prestigious awards, including the Morton Grove Rasmussen Prize from the American Association of Blood Banks and the 11th International Prix Henri Chaigneau from l’association francaise des hemophiles.Specialties: blood safety, plasma protein manufacture, viral testing and inactivation, blood viruses, biologics, R&D